1178 related articles for article (PubMed ID: 33161318)
1. Endothelial dysfunction in COVID-19: Current findings and therapeutic implications.
Nägele MP; Haubner B; Tanner FC; Ruschitzka F; Flammer AJ
Atherosclerosis; 2020 Dec; 314():58-62. PubMed ID: 33161318
[TBL] [Abstract][Full Text] [Related]
2. Endothelial dysfunction in COVID-19: a position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular Science.
Evans PC; Rainger GE; Mason JC; Guzik TJ; Osto E; Stamataki Z; Neil D; Hoefer IE; Fragiadaki M; Waltenberger J; Weber C; Bochaton-Piallat ML; Bäck M
Cardiovasc Res; 2020 Dec; 116(14):2177-2184. PubMed ID: 32750108
[TBL] [Abstract][Full Text] [Related]
3. The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies.
Albini A; Di Guardo G; Noonan DM; Lombardo M
Intern Emerg Med; 2020 Aug; 15(5):759-766. PubMed ID: 32430651
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.
Shukla AK; Banerjee M
High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):129-139. PubMed ID: 33635533
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 and cardiovascular consequences: Is the endothelial dysfunction the hardest challenge?
Del Turco S; Vianello A; Ragusa R; Caselli C; Basta G
Thromb Res; 2020 Dec; 196():143-151. PubMed ID: 32871306
[TBL] [Abstract][Full Text] [Related]
6. Statins and PCSK9 inhibitors: What is their role in coronavirus disease 2019?
Barkas F; Milionis H; Anastasiou G; Liberopoulos E
Med Hypotheses; 2021 Jan; 146():110452. PubMed ID: 33333472
[TBL] [Abstract][Full Text] [Related]
7. Endothelial cells and SARS-CoV-2: An intimate relationship.
Barbosa LC; Gonçalves TL; de Araujo LP; Rosario LVO; Ferrer VP
Vascul Pharmacol; 2021 Apr; 137():106829. PubMed ID: 33422689
[TBL] [Abstract][Full Text] [Related]
8. Protecting older patients with cardiovascular diseases from COVID-19 complications using current medications.
Alves M; Fernandes MA; Bahat G; Benetos A; Clemente H; Grodzicki T; Martínez-Sellés M; Mattace-Raso F; Rajkumar C; Ungar A; Werner N; Strandberg TE;
Eur Geriatr Med; 2021 Aug; 12(4):725-739. PubMed ID: 34031865
[TBL] [Abstract][Full Text] [Related]
9. Associastion of In-hospital Use of Statins, Aspirin, and Renin-Angiotensin-Aldosterone Inhibitors with Mortality and ICU Admission Due to COVID-19.
Vahedian-Azimi A; Rahimibashar F; Najafi A; Kidde J; Shahriary A; Shojaei S; Pourhoseingholi MA; Jamialahmadi T; Sahebkar A
Adv Exp Med Biol; 2021; 1327():205-214. PubMed ID: 34279841
[TBL] [Abstract][Full Text] [Related]
10. Covid-19 and the cardiovascular system: a comprehensive review.
Azevedo RB; Botelho BG; Hollanda JVG; Ferreira LVL; Junqueira de Andrade LZ; Oei SSML; Mello TS; Muxfeldt ES
J Hum Hypertens; 2021 Jan; 35(1):4-11. PubMed ID: 32719447
[TBL] [Abstract][Full Text] [Related]
11. An Assessment on Impact of COVID-19 Infection in a Gender Specific Manner.
Agrawal H; Das N; Nathani S; Saha S; Saini S; Kakar SS; Roy P
Stem Cell Rev Rep; 2021 Feb; 17(1):94-112. PubMed ID: 33029768
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin-converting enzyme 2 and kidney diseases in the era of coronavirus disease 2019.
Suh SH; Ma SK; Kim SW; Bae EH
Korean J Intern Med; 2021 Mar; 36(2):247-262. PubMed ID: 33617712
[TBL] [Abstract][Full Text] [Related]
13. Pathophysiological Association of Endothelial Dysfunction with Fatal Outcome in COVID-19.
Maruhashi T; Higashi Y
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34066226
[TBL] [Abstract][Full Text] [Related]
14. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
15. COVID-19, hypertension, and RAAS blockers: the BRACE-CORONA trial.
Mancia G
Cardiovasc Res; 2020 Dec; 116(14):e198-e199. PubMed ID: 33245754
[No Abstract] [Full Text] [Related]
16. Therapeutic approaches targeting renin-angiotensin system in sepsis and its complications.
Ning L; Rong J; Zhang Z; Xu Y
Pharmacol Res; 2021 May; 167():105409. PubMed ID: 33465472
[TBL] [Abstract][Full Text] [Related]
17. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial.
Lopes RD; Macedo AVS; de Barros E Silva PGM; Moll-Bernardes RJ; Feldman A; D'Andréa Saba Arruda G; de Souza AS; de Albuquerque DC; Mazza L; Santos MF; Salvador NZ; Gibson CM; Granger CB; Alexander JH; de Souza OF;
Am Heart J; 2020 Aug; 226():49-59. PubMed ID: 32502882
[TBL] [Abstract][Full Text] [Related]
18. Understanding the renin-angiotensin-aldosterone-SARS-CoV axis: a comprehensive review.
Ingraham NE; Barakat AG; Reilkoff R; Bezdicek T; Schacker T; Chipman JG; Tignanelli CJ; Puskarich MA
Eur Respir J; 2020 Jul; 56(1):. PubMed ID: 32341103
[TBL] [Abstract][Full Text] [Related]
19. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19.
Cheng H; Wang Y; Wang GQ
J Med Virol; 2020 Jul; 92(7):726-730. PubMed ID: 32221983
[TBL] [Abstract][Full Text] [Related]
20. The Role of Endothelium in COVID-19.
Ionescu M; Stoian AP; Rizzo M; Serban D; Nuzzo D; Mazilu L; Suceveanu AI; Dascalu AM; Parepa IR
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
